Gene in so cells make the enzyme — Tutorial

A one-time treatment can put a missing gene into a child’s body so their cells make an enzyme that used to be missing. Some rare inherited brain diseases happen because a child’s cells cannot make one needed enzyme. Without that tool, a complex sugar builds up and slowly hurts brain cells. A one-time treatment path can put a working gene in so cells make the enzyme. First-treatment news is not every child tomorrow — and inventing stays open.

Page	Title	Concept (one line)	When the tutor offers it	Illustration
01	Missing enzyme, sugar buildup	No enzyme tool → sugar buildup hurts brain cells over time.	First beat, before gene-in mechanism.	01
02	Gene in, cells make enzyme	Working gene → cells make enzyme → buildup cleared.	After missing-enzyme harm; before regulatory news.	02
03	First approved treatment	Sep 2026 first-treatment news — capability class, not a brand answer.	After gene-in mechanism; before the one idea.	03
04	One-time path: gene to enzyme	A one-time treatment can put a missing gene into a child’s body so their cells make an enzyme that used to be missing.	Core one idea after the news.	04
05	Hope with honest limits	New hope and still-true limits both belong in the story.	After the one idea; before eligibility.	05
06	Not for every child yet	Eligibility, timing, and access still matter.	After hope/limits; before invent.	06
07	Invent an everyday change at Softglen	Open invent for Softglen — no prescribed brand.	Last page / invent gate.	07

Sources

• FDA Press Announcement — first FDA-approved gene therapy for a rare childhood brain disease caused by a missing enzyme (17 Sep 2026)
• FDA.govdelivery bulletin — same announcement (17 Sep 2026)
• Company approval press via BioSpace — one-time gene therapy that restores the missing enzyme (17 Sep 2026; org self-report)
• ClinicalTrials.gov — pivotal trial for the approved one-time gene-to-enzyme pathway
• RTT News — FDA approval restatement (18 Sep 2026)